How to read a tag. Only
verified counts toward a score — it means a typed connector
resolved this against a primary US federal record.
unconfirmed means the Verifier checked and could not confirm,
which very often means the source could not be queried at all rather than that
the claim is doubtful. refuted means a primary source
contradicts it. unverified means nothing has checked it yet.
claim 1verifiedUS
CMS established a national coverage determination titled "Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure (CRF) Consequent to Chronic Obstructive Pulmonary Disease (COPD)", carried in the Medicare National Coverage Determinations Manual Chapter 1, Part 4, Section 240.9, with an effective date of 2025-06-09
jurisdiction: US — confidence: verified — note: all three elements read off the NCD Manual itself, not off the coverage-database web page. Title matches verbatim; the manual part is chapter 1 part 4; the section header reads "(Rev. 13808; Issued: 05-29-26; Effective: 06-09-25; Implementation: 10-22-25)", so the…the full check claimed effective date 2025-06-09 is confirmed. The manual also records "(This NCD last reviewed June 2025.)" — source: ncd 240.9 --expect "Chronic Obstructive Pulmonary Disease" --jurisdiction US → verified, CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=240.9. (The ncd connector initially returned unconfirmed because pypdf was not installed in this environment; the dependency from requirements.txt was installed and the lookup re-run.)
claim 2unconfirmedUS
The national coverage analysis that produced NCD 240.9 is identified by CMS as CAG-00465N
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason, not a negative finding. No connector in this repo reads the CMS national coverage analysis / decision-memo database (ncacal-decision-memo), and the NCD Manual section — which is the only CMS primary source reachable here — does not…the full check carry the tracking number. Its absence from the manual is not evidence the tracking number is wrong; NCD Manual sections do not generally cite their NCA tracking sheet. Needs a human retrieval of the decision memo — source: ncd 240.9 --expect "CAG-00465N" --jurisdiction US → unconfirmed: section exists and was read in full, text does not contain 'CAG-00465N'. CMS Pub. 100-3, chapter 1 part 4, section=240.9.
claim 3verifiedUS
CMS implemented NCD 240.9 through a Change Request transmittal published at cms.gov/files/document/r13808ncd.pdf (transmittal number read from that filename as R13808NCD)
jurisdiction: US — confidence: verified — note: verified on the transmittal number and the implementation date, from the manual's own revision header rather than from the filename: the section 240.9 header reads "(Rev. 13808; Issued: 05-29-26; Effective: 06-09-25; Implementation: 10-22-25)", and the connector's…the full check source_ref independently records the part as Rev. 13808. So Rev./Transmittal 13808 is the instrument that carried this section into the manual, and the implementation date the Generator left open is 2025-10-22. Not verified: the PDF at that URL was not fetched (no connector reads CMS transmittal PDFs) and the associated Change Request number is still unknown — source: ncd 240.9 --jurisdiction US → verified, CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4 (Rev. 13808, issued 05-29-26), section=240.9.
claim 4unconfirmedUS
NCD 240.9 sets national coverage criteria for both respiratory assist devices (HCPCS E0470/E0471) and home mechanical ventilators for chronic respiratory failure consequent to COPD, replacing, for that population, coverage determinations previously left to the discretion of the Medicare Administrative Contractors
jurisdiction: US — confidence: unconfirmed — note: compound claim, and it splits three ways. Confirmed: the NCD does set national criteria for both device categories — section B.I covers "Respiratory Assist Devices (RADs)" with and without a backup rate feature, and section B.II covers "Home Mechanical…the full check Ventilators", both for CRF consequent to COPD. Not confirmed: the NCD text names no HCPCS code at all — neither E0470 nor E0471 appears in it, so the code-to-NCD linkage is this repo's own and not CMS's wording in this document (the same mismatch recorded on idea-001 claim 9). Contradicted in part: section D of the NCD reads "Medicare Administrative Contractors (MACs) may make reasonable and necessary determinations under section 1862(a)(1)(A) of the Social Security Act for any patient seeking initial coverage or continued coverage for RADs or HMVs used as treatment of chronic respiratory failure consequent to COPD." MAC discretion is expressly preserved, not replaced, so "replacing ... determinations previously left to the discretion of the MACs" overstates what the final NCD does. Left unconfirmed rather than refuted because the national criteria themselves are real; a human should decide whether the word "replacing" survives section D — source: ncd 240.9 --expect "home mechanical ventilator" --jurisdiction US → verified; ncd 240.9 --expect "E0471" --jurisdiction US → unconfirmed (text does not contain it); ncd 240.9 --expect "E0470" --jurisdiction US → unconfirmed (text does not contain it); ncd 240.9 --expect "Medicare Administrative Contractor" --jurisdiction US → verified, but in the section-D sentence quoted above. All: CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4, section=240.9.
claim 5refutedUS
The coverage criteria associated with NCD 240.9 contemplate a respiratory assist device with a back-up rate feature delivering high-intensity noninvasive ventilation, characterised as inspiratory positive airway pressure above 20 cm H2O together with a back-up respiratory rate of at least 14 breaths per minute
jurisdiction: US — confidence: refuted — note: the Verifier question the Generator asked for is settled, and the pressure figure is wrong. The final NCD defines the term in one sentence: "By the end of the initial 6-month period, a RAD with backup rate feature must be utilized as high intensity therapy, defined as…the full check a minimum IPAP ≥ 15 cm H2O and backup respiratory rate of at least 14 breaths per minute." The back-up-rate half of the claim is verbatim correct. The pressure half is not: the threshold in the final determination is IPAP ≥ 15 cm H2O, and the string "20 cm H2O" does not occur anywhere in the section. Recorded as refuted rather than unconfirmed because this is not a wording variance — the NCD's own definition of the same term states a different number, which is the proposed-versus-final distinction the Generator flagged. Note for the Scorer: the connector's own status on the phrase lookup was unconfirmed (a phrase miss is never refuted by the tool); the refuted tag is recorded against the quoted contradicting sentence, and a human may overrule it from that quote. Note also this loosens rather than tightens the coverage envelope, and that the 20 cm H2O figure most likely came from trial practice, not from CMS: HOT-HMV's median ventilator setting was an IPAP of 24 cm H2O (IQR 22-26) — see claim 15 — source: ncd 240.9 --expect "20 cm H2O" --jurisdiction US → unconfirmed: "exists and was read, but its text does NOT contain the phrase '20 cm H2O'"; ncd 240.9 --expect "IPAP" --jurisdiction US → verified, returning the IPAP ≥ 15 cm H2O sentence quoted above. Both: CMS Pub. 100-3 Medicare NCD Manual, chapter 1 part 4, section=240.9.
claim 6unconfirmedUS
The DME MAC local coverage determination L33800, "Respiratory Assist Devices", was revised to align with NCD 240.9, and its companion policy article is A52517
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason, not a source silence. Nothing about an LCD was looked up in either direction. The only code-keyed instrument here is coverage, which reads a cached CMS coverage-policy index that is not present in this environment, and even with…the full check the file it answers "does a policy name this code", never "what does L33800 say" or "was it revised". No connector in this repo reads LCD or policy-article text by ID. Settling this needs a human retrieval of L33800/A52517 (and of the proposed DL33800 and response-to-comments A58822 the Generator also saw) — source: coverage E0471 --jurisdiction US → unconfirmed: "No local cache at data/medicare_coverage_policies.csv — Medicare coverage policy for E0471 cannot be checked until it exists."
claim 7unconfirmedUS
HCPCS code E0471 carries the descriptor "Respiratory assist device, bi-level pressure capability, with back-up rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)"
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason. The HCPCS Level II cache is absent in this environment, so the descriptor was not checked against a CMS release in either direction. This is a missing-file gap and is not evidence that the code or descriptor is wrong. Worth noting…the full check the code number itself is used, unchallenged, throughout the NCD-aligned DME literature; only the verbatim descriptor is open — source: hcpcs E0471 --jurisdiction US → unconfirmed: "No local cache at data/hcpcs_level_ii.csv — HCPCS Level II code E0471 cannot be checked until it exists. See data/README.md."
claim 8unconfirmedUS
Medicare pays respiratory assist devices with bi-level capability and a back-up rate as capped rental items of durable medical equipment rather than as items requiring frequent and substantial servicing, a classification made in a rule published in the Federal Register on 2006-01-27 titled "Medicare Program; Payment for Respiratory Assist Devices With Bi-Level Capability and a Backup Rate", Federal Register document number 06-798
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason — nothing was queried. The policy connector rejected the citation before making a request: "'06-798' is not a Federal Register document number. The format is YYYY-NNNNN". Pre-2007 Federal Register documents use the older…the full check numbering scheme (06-nnn / E6-nnnn) that this connector's validator does not accept, so the 2006 rule cannot be reached from here at all. A second, independent route to the payment-category half of the claim is also closed: the DMEPOS payment cache is absent (see claim 10). No web substitute was used. Needs either a human fetch of the 2006 rule or a connector fix for legacy FR document numbers — source: policy 06-798 --expect-type rule --expect "capped rental" --jurisdiction US → unconfirmed: document-number format rejected, nothing queried.
claim 9unconfirmedUS
TAM component 1 (code and annual volume) — HCPCS E0471 carries non-zero national Medicare fee-for-service utilization, and the annual allowed-services count for the code is reported at HCPCS-code level in CMS's "Medicare Durable Medical Equipment, Devices & Supplies by Referring Provider and Service" public use file
jurisdiction: US — confidence: unconfirmed — note: unconfirmed because the file is missing, not because the code has no volume — the connector says so in terms: "E0471 is a supplier-billed DMEPOS code, and the cached release (medicare_procedure_volumes.csv) covers physician-billed services — it carries essentially…the full check no E-prefixed codes at all. Nothing was looked up in either direction. This is a missing-file gap, not evidence that the code has no volume." The release that would answer it is CMS "Medicare Durable Medical Equipment, Devices & Supplies — by Geography and Service" (data.cms.gov), uncached here; see docs/backlog.md 1.13. The claim's own structure — "the number exists and is retrievable from this named file" — is the right shape and survives intact; only the retrieval is blocked. Carry forward, when it is retrieved, that Medicare FFS excludes Medicare Advantage, commercial, Medicaid, VA and cash-pay, so any figure is a floor on US volume and never a market size — source: procedures E0471 --jurisdiction US → unconfirmed (DMEPOS code absent from the cached physician-billed release).
claim 10unconfirmedUS
TAM component 2 (price per unit) — the Medicare DMEPOS fee schedule publishes a monthly rental allowable for HCPCS E0471, and that allowable multiplied by the capped-rental period is the gross Medicare revenue per enrolled patient
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason. The payment cache is absent in this environment, so no allowable was retrieved and the rural/non-rural and competitive-bidding question the Generator asked about could not be examined either. Missing-file gap, not a finding that no…the full check allowable exists — source: payment E0471 --jurisdiction US → unconfirmed: "No local cache at data/hcpcs_payment_rates.csv — payment rate for E0471 cannot be checked until it exists."
claim 11unconfirmedUS
TAM component 3 (addressable share) — Generator assumption, unsourced: the share of US adults with diagnosed COPD who have chronic hypercapnic respiratory failure meeting NCD 240.9's coverage criteria is a low single-digit percentage of the diagnosed COPD population, and the near-term addressable group is narrower still — patients identified in the weeks after a hospitalised exacerbation, which is the population HOT-HMV enrolled
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent a human-attached licensed or primary source; the market connector is unverifiable by design and no agent pass can close this. One partial anchor is now on the record from a primary source, and it is worth keeping: HOT-HMV screened…the full check 2,021 patients to enrol 124 eligible (claim 15, PubMed PMID 28528348) — a 6.1% screen-to-eligible ratio in a trial population already selected for post-exacerbation hypercapnia. That is a trial-recruitment figure, not a prevalence estimate, and must not be used as one — source: market "share of US adults with diagnosed COPD who have chronic hypercapnic respiratory failure meeting NCD 240.9 coverage criteria is a low single-digit percentage" → unverifiable: "no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand."
claim 12unconfirmedUS
TAM component 4 (population base) — approximately 16 million US adults have a diagnosed chronic obstructive pulmonary disease
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed here. No connector in this repo reaches CDC/BRFSS prevalence data (the structural gap already recorded on idea-014), and market is unverifiable by design. Needs a human-attached primary table; the figure is neither confirmed nor challenged…the full check by anything run this pass — source: market "approximately 16 million US adults have diagnosed chronic obstructive pulmonary disease" → unverifiable: "no free, authoritative, machine-queryable source."
claim 13unconfirmedUS
CPT 95811 is an existing Category I code covering polysomnography for age 6 years or older with initiation of continuous positive airway pressure therapy or bilevel ventilation, attended by a technologist
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed by design — the claim is about the descriptor text, and CPT descriptors are AMA-licensed and cannot be reproduced or scraped (phase2-spec.md Section 3). Either a human attaches a licensed AMA/vendor source or the claim is rescoped. What…the full checkis now on the record from a free CMS file is that the code number is live and payable on the 2026 PFS — see claim 14, where rvu 95811 returned verified — which settles the "existing Category I code" half without touching the descriptor — source: cpt 95811 → unverifiable: "CPT descriptors are AMA-licensed and cannot be scraped or reproduced verbatim ... no agent pass can close it."
claim 14unconfirmedUS
The payment setting difference this candidate depends on has three sides, none of whose amounts the Generator retrieved: (a) home delivery is paid as a monthly capped-rental DME allowable under E0471 with no facility fee; (b) the attended titration study it is intended to displace (CPT 95811) is performed in a sleep laboratory or hospital and is paid with a facility component; (c) the exacerbation readmissions the therapy is intended to postpone are paid under the inpatient prospective payment system
jurisdiction: US — confidence: unconfirmed — note: one of the three sides now has a number and the other two are blocked on missing files. (b) partly answered:rvu 95811 → verified, local cache of the CMS PFS RVU file, 2026, status A, CF 33.5675 — global (no modifier) work 2.54 + PE 18.37 + MP 0.28 → $711.30;…the full check technical component (modifier TC) $586.76, of which the PE portion is $581.05; professional component (modifier 26) $124.54. So roughly 82% of the payment for an attended titration study is the technical component, which is the facility-side money the claim is about. National unadjusted, no GPCI; and the connector's own caveat applies — this says what the PFS pays, never that a facility is separately paid (that is apc/drg). (a) blocked: no DMEPOS allowable, cache absent (claim 10). (c) blocked and the codes still unidentified: the MS-DRG cache is absent, so MS-DRGs 190/191/192 were neither confirmed nor refuted and must continue to be treated as unidentified — source: rvu 95811 --jurisdiction US → verified, local cache of CMS PFS RVU file, code=95811, year=2026; drg 190 --jurisdiction US → unconfirmed: "No local cache at data/ms_drg_weights.csv"; payment E0471 --jurisdiction US → unconfirmed: no local cache.
claim 15verifiedUS
In the HOT-HMV randomised clinical trial (Murphy PB et al., JAMA, 2017-06-06, volume 317, issue 21, pages 2177-2186), adding home noninvasive ventilation to home oxygen therapy in patients with persistent hypercapnia after a life-threatening COPD exacerbation extended median admission-free survival to 4.3 months versus 1.4 months for home oxygen alone, while 12-month mortality did not differ significantly (28.1% versus 32.2%)
jurisdiction: US — confidence: verified — note: every number checks out against the PubMed record of the paper. "The median time to readmission or death was 4.3 months (IQR, 1.3-13.8 months) in the home oxygen plus home NIV group vs 1.4 months (IQR, 0.5-3.9 months) in the home oxygen alone group, adjusted hazard ratio…the full check of 0.49 (95% CI, 0.31-0.77; P = .002)." On mortality: "At 12 months, 16 patients had died in the home oxygen plus home NIV group vs 19 in the home oxygen alone group" — against 57 and 59 randomised, that is 28.1% and 32.2% exactly as claimed, and the abstract reports no significant difference. The PMID the Generator could not confirm is confirmed: 28528348, JAMA 2017, type "Randomized Controlled Trial", registered NCT00990132. Two riders. The record returns year only, so the 2017-06-06 date and the volume/issue/page citation are still unchecked. And the trial is UK-conducted ("recruited from 13 UK centres between 2010 and 2015") — the jurisdiction: US tag on this line is wrong in substance; this is clinical evidence about a mechanism, carrying no US regulatory or reimbursement weight, exactly as the Generator warned. Two figures worth carrying into other claims: 2,021 screened for 124 eligible (claim 11), and median settings of IPAP 24 cm H2O (IQR 22-26), EPAP 4, backup rate 14 (claim 5) — source: literature-detail 28528348 → found, PubMed PMID=28528348 (efetch), https://pubmed.ncbi.nlm.nih.gov/28528348/. Instrument caveat: literature-detail returns a ScanResult, which carries no confidence tag of its own and is not replayable by recheck_claims.py; the verified tag here is recorded against the quoted structured abstract retrieved from PubMed, which is the primary record for the published paper.
claim 16unconfirmedUS
In that same trial, noninvasive ventilation was titrated to overnight measures of transcutaneous CO2 in order to control nocturnal hypoventilation
jurisdiction: US — confidence: unconfirmed — note: the single load-bearing mechanism claim is still not anchored, and this is a real source silence, not a tooling gap. The full PubMed structured abstract for PMID 28528348 was retrieved and read; it describes the design, the population, the interventions and the…the full check median ventilator settings (IPAP 24, EPAP 4, backup rate 14) but says nothing about transcutaneous CO2 or about what the titration target was. The connector flags the limit itself: "structured abstract — deeper than a title, still not appraised: no methods". The titration protocol lives in the paper's methods section, which no connector in this repo can reach (JAMA full text is paywalled). What is not the case is that the trial is silent on CO2 — enrolment required Paco2 > 53 mm Hg and outcomes were framed around hypercapnia; it is specifically the transcutaneous, overnight, titration-target assertion that is unsupported. This should be the first item a human closes: it is the premise of the whole device — source: literature-detail 28528348 → found, PubMed PMID=28528348 (efetch); abstract contains no mention of transcutaneous CO2 or of a titration target.
claim 17verifiedUS
FDA has published a document titled "Cutaneous Carbon Dioxide (PcCO2) and Oxygen (PcO2) Monitors - Class II Special Controls Guidance Document for Industry and FDA", indicating that transcutaneous CO2 monitors are regulated as Class II devices subject to special controls
jurisdiction: US — confidence: verified — note: verified from the regulation text itself, which is a stronger source than the guidance page the Generator saw and closes the gap the Generator left open. 21 CFR 868.2480 reads: "§ 868.2480 Cutaneous carbon dioxide (PcCO2) monitor. (a) Identification. A cutaneous carbon…the full check dioxide (PcCO2) monitor is a noninvasive heated sensor and a pH-sensitive glass electrode placed on a patient's skin, which is intended to monitor relative changes in a hemodynamically stable patient's cutaneous carbon dioxide tension as an adjunct to arterial carbon dioxide tension measurement. (b) Classification. Class II (special controls). The special control for this device is FDA's 'Class II Special Controls Guidance Document: Cutaneous Carbon Dioxide (PcCO2) and Oxygen (PcO2) Monitors; Guidance for Industry and FDA.'" The CFR names the guidance by title (word order differs from the claim's rendering; it is the same document) and states the Class II / special-controls status directly. The two fields the Generator did not identify are now identified: CFR section 21 CFR 868.2480, product code LKD, "Monitor, Carbon-Dioxide, Cutaneous", device class 2, review panel AN. Two riders: the guidance document's own text was not opened (no connector reaches FDA guidance, and fda.gov gates automated fetches), so what it requires is unread; and note the CFR's identification frames the device as an adjunct to arterial measurement in a hemodynamically stable patient, which is narrower than this candidate's intended use of overnight home recording as a titration input — that gap is a pre-submission question, not a database fact — source: regulation 868.2480 --title 21 --expect "special controls" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-16, section=868.2480; classification --device-name "monitor, carbon dioxide" --jurisdiction US → verified, openFDA device/classification product_code=LKD.
claim 18verifiedUS
21 CFR 868.5895 is the classification regulation for continuous ventilators, and the Philips Respironics BiPAP AVAPS Ventilatory Support System has been described as classified under that regulation with product code MNS, "ventilator, continuous, non-life-supporting"
jurisdiction: US — confidence: verified — note: all three legs confirmed against primary records, and the K-number the Generator could not capture is K102465. (1) eCFR: "§ 868.5895 Continuous ventilator. (a) Identification. A continuous ventilator (respirator) is a device intended to mechanically control or assist…the full check patient breathing by delivering a predetermined percentage of oxygen in the breathing gas ... (b) Classification. Class II (performance standards)." (2) openFDA classification for product code MNS: "Device class 2: Ventilator, Continuous, Non-Life-Supporting (regulation 868.5895, review panel AN)" — the exact pairing the claim asserts. (3) The device: 510(k) K102465, "BIPAP AVAPS VENTILATORY SUPPORT SYSTEM", Respironics, Inc., decided 2011-03-24, and the openFDA record for that clearance carries product_code=MNS. Checked against this file's stated intended_use: — prescription home bi-level NIV with a back-up rate for adults with CRF consequent to COPD, no life support, no automatic setting changes; a change of indication toward life-supporting use or closed-loop control would move this off MNS and invalidate the finding. Not established by this lookup: that this candidate device falls inside MNS. Its Indications for Use, retrieved from the K102465 summary, cover "non-invasive ventilatory support to treat adult and pediatric (> 7 years of age; > 40 lbs) patients with obstructive Sleep Apnea (OSA) and Respiratory Insufficiency ... in the hospital or home" — it names neither CRF consequent to COPD nor any CO2-recording or titration-recommendation function, so the combined-function half of this candidate has no predicate indication here — source: regulation 868.5895 --title 21 --expect "continuous ventilator" --jurisdiction US → verified, eCFR versioner title-21, issue 2026-09-16, section=868.5895; classification --product-code MNS --jurisdiction US → verified, openFDA device/classification product_code=MNS; 510k "AVAPS" --applicant "Respironics" --jurisdiction US → verified, openFDA device/510k k_number=K102465; clearance-summary K102465 --jurisdiction US → verified, FDA 510(k) summary K102465 (https://www.accessdata.fda.gov/cdrh_docs/pdf10/K102465.pdf).
claim 19unconfirmedUS
No FDA-cleared device marketed in the US combines a home respiratory assist device with back-up rate and an integrated transcutaneous CO2 recording channel driving practitioner-approved titration recommendations
jurisdiction: US — confidence: unconfirmed — note: re-run keyed on product code as the Generator asked, and it still cannot be verified — an absence-of-evidence claim cannot be closed by a database that returns nulls for devices that exist. What the product-code-keyed scans show: MNS (continuous ventilator,…the full check non-life-supporting) returns 43 clearances over 2000-01-01 to 2026-09-18, none of whose device names mentions CO2, carbon dioxide or transcutaneous; LKD (cutaneous carbon-dioxide monitor, the code identified this pass — see claim 17) returns 9 clearances over the same window, every one a standalone monitor (Sentec SDMS ×4 including K232516 tCOM+ 2024, Radiometer TCM40 and TOSCA, Linde TOSCA 500, Philips IntelliVue TCG10, Perimed PeriFlux 6000) and none a respiratory assist device. So the two halves are cleared under two disjoint product codes with no overlap in the record. That is consistent with the claim and is still not evidence for it, and it must not be scored as white space: a combined device could be cleared under either code without a name that a scan would catch, and clearances is a Stage 0 scan that issues no confidence tag at all — source: clearances --product-code MNS --since 2000-01-01 --until 2026-09-18 --limit 100 --jurisdiction US → found, 43 records, openFDA device/510k; clearances --product-code LKD --since 2000-01-01 --until 2026-09-18 --limit 50 --jurisdiction US → found, 9 records, openFDA device/510k.
claim 20verifiedUS
Federal Register document 2026-16368 (91 FR 51710) states, among the eligibility criteria for the RAPID coverage pathway, "Separately payable devices that can, if approved, be billed to Medicare"
jurisdiction: US — confidence: verified — note: the phrase is in the document verbatim, in the eligibility list, in context: "Not already the subject of a controlling Medicare NCD; Separately payable devices that can, if approved, be billed to Medicare; and Not otherwise excluded from coverage through law or…the full check regulation." Two things the lookup settles that cut against reading much into this. First, the instrument is a Notice, published 2026-08-11, with a comment period closing 2026-10-13 and no effective date recorded — it states what CMS intends, not a settled requirement, and a published intention is not a policy operating. Second, and more directly: the first criterion in that same sentence is "Not already the subject of a controlling Medicare NCD" — and this candidate's whole reimbursement premise is that NCD 240.9 controls its population (claims 1 and 4). On the document's own words the candidate appears excluded by the criterion immediately preceding the one the Generator cited, which strengthens rather than weakens the Generator's conclusion that no RAPID tailwind should be credited here. Whether that reading is right is interpretation, which this connector does not settle — source: policy 2026-16368 --expect "Separately payable devices that can, if approved, be billed to Medicare" --jurisdiction US → verified, Federal Register document_number=2026-16368 (91 FR 51710), "Medicare Program; Regulatory Alignment for Predictable and Immediate Device (RAPID) Coverage Pathway" (Notice, published 2026-08-11, HHS / CMS).
claim 21verifiedUS
Federal Register document 2026-16368 (91 FR 51710) limits the RAPID coverage pathway to Class II and Class III FDA Breakthrough-designated devices
jurisdiction: US — confidence: verified — note: confirmed in the document's own words: "RAPID coverage pathway will provide accelerated Medicare beneficiary access to certain eligible Class II and Class III U.S. Food and Drug Administration (FDA) Breakthrough-designated Devices." Same instrument caveat as claim 20 — a…the full check Notice with a comment period closing 2026-10-13, so this is a stated intention, not law, and it may change before anything is finalised. The Generator's planning posture (no Breakthrough assumption, no coverage-timing tailwind credited to this file) is supported by the text and is the conservative read — source: policy 2026-16368 --expect "Breakthrough" --jurisdiction US → verified, Federal Register document_number=2026-16368 (91 FR 51710), Notice, published 2026-08-11, HHS / CMS.
claim 22verifiedUS
Philips issued a voluntary recall notification on 2021-06-14 covering certain ventilators, CPAP devices and bi-level positive airway pressure devices, on the basis of health risks associated with polyester-based polyurethane sound-abatement foam, affecting on the order of 15 million devices worldwide
jurisdiction: US — confidence: verified — note: the recall event, its exact date, the device categories and the stated basis are all confirmed against openFDA device-recall records. Six records carry event date 2021-06-14, all with the same reason text — "The polyester-based polyurethane (PE-PUR) foam may degrade into…the full check particles which may enter the device's air pathway and be ingested..." — and between them they span exactly the three categories the claim names: Z-1956-2021 (Trilogy 100/200, Garbin Plus, Aeris — ventilators), Z-1957-2021 and Z-1958-2021 (A-Series BiPAP Hybrid A30, BiPAP A40, BiPAP A30 — bi-level), Z-1972-2021 (E30), Z-1973-2021 (DreamStation ASV, DreamStation ST, AVAPS) and Z-1974-2021 (SystemOne Q-Series, DreamStation — CPAP). All six are still "Open, Classified" as of this pass. Two exclusions from the tag. The "on the order of 15 million devices worldwide" figure appears in no openFDA record — it is a company/press number and stays unconfirmed. And the instrument, recalls, is a Stage 0 scan whose ScanResult carries no confidence tag and is not replayable by recheck_claims.py; the tag is recorded against the six quoted primary records, each with its own product-resolution source_ref. Note for competitive-intensity scoring: the same firm-and-year scan returns 12 further 2021 recalls (Trilogy Evo software, 2021-07-26 and 2021-12-22; BiPAP V30 Auto / A40 / A30 motor assemblies, 2021-04-06, since terminated) — source: recalls --firm "Philips Respironics" --since 2021-01-01 --until 2021-12-31 --limit 20 --jurisdiction US → found, 18 records, openFDA device/recall, including product_res_number=Z-1956-2021, Z-1957-2021, Z-1958-2021, Z-1972-2021, Z-1973-2021, Z-1974-2021, all dated 2021-06-14.
claim 23unconfirmedUS
On 2024-04-09 a federal district court entered a consent decree between the United States (Department of Justice on behalf of FDA) and Philips Respironics which, until specified requirements are met, restricts the sale of new CPAP and bi-level sleep-therapy devices and certain other respiratory care devices in the United States from named Philips Respironics facilities
jurisdiction: US — confidence: unconfirmed — note: unconfirmed for a tooling reason — no connector in this repo reaches a court docket, a DOJ filing or an FDA enforcement action.policy reads the Federal Register only, which does not carry consent decrees; recalls and maude are device-event scans and say…the full check nothing about an enforcement agreement. Neither the decree nor its current status was checked, and no web substitute was used. The Generator's own flag stands and is the important half: the Scores table leans on this decree as the one opening in a crowded field, and whether the sale restrictions are still in force in September 2026 is unknown to this file. A two-year-old enforcement dislocation is the kind of fact most likely to have moved. This needs a human to read the docket or Philips' current investor filings before any competitive-intensity score rests on it — source: no connector covers court dockets or FDA enforcement actions; nothing was queried.
claim 24unconfirmedUS
ResMed markets the AirCurve 10 ST-A with iVAPS, and Philips Respironics markets the BiPAP AVAPS, as home bi-level devices with a back-up rate and volume-assured pressure support; SenTec markets the SenTec Digital Monitoring System with the V-Sign sensor for transcutaneous CO2 monitoring, including described use in the patient's home under clinical supervision
jurisdiction: US — confidence: unconfirmed — note: compound over three devices; two resolve cleanly to cleared records, one does not, and "markets" is in any case a commercial fact that a clearance database cannot establish — a cleared device may never have shipped. SenTec: confirmed, and precisely. 510(k)…the full check K071672, "SENTEC DIGITAL MONITORING SYSTEM", Sentec AG, 2007-09-12; its Indications for Use read "The SenTec Digital Monitoring System — consisting of the SenTec Digital Monitor (SDM), the V-Sign™ Sensor and Accessories — is indicated for continuous, non-invasive patient monitoring ... in hospitals, hospital-type facilities, intra-hospital transport environments, and — if under clinical supervision — home environments." That is the V-Sign sensor and the home-under-clinical-supervision language, both verbatim, from the cleared indication. A later clearance K151329 (2015-12-17) names the V-Sign Sensor explicitly, and K232516 (2024-05-17) is the current SDMS tCOM+. Philips: confirmed as a cleared device — K102465, BIPAP AVAPS VENTILATORY SUPPORT SYSTEM, product code MNS (see claim 18). ResMed: not confirmed under the name claimed. openFDA returns no 510(k) for device_name "AirCurve 10 ST-A", "AirCurve 10 ST" or "iVAPS". The nearest record is K161492, "Juno VPAP ST-A", Resmed Ltd., 2017-01-19, whose Indications for Use do name the mode: "The Juno VPAP ST-A is indicated to provide noninvasive ventilation for patients weighing more than 30lbs (13 kg) with respiratory insufficiency or obstructive sleep apnoea (OSA). The iVAPS mode is indicated for patients weighing more than 66lbs (30 kg). The Juno VPAP ST-A is intended for home and hospital use." Whether "Juno VPAP ST-A" is the same platform marketed in the US as "AirCurve 10 ST-A" is a brand-to-clearance mapping this repo cannot make from a database, so it is left for a human. Note also that no IFU retrieved here uses the phrase "back-up rate" — the back-up-rate characterisation of any of these devices is unverified — source: 510k "SenTec Digital Monitoring System" --applicant "SenTec" --jurisdiction US → verified, openFDA device/510k k_number=K071672; clearance-summary K071672 --jurisdiction US → verified, FDA 510(k) summary K071672 (https://www.accessdata.fda.gov/cdrh_docs/pdf7/K071672.pdf); 510k "AirCurve 10 ST-A" --applicant "ResMed" --jurisdiction US → refuted: "No 510(k) record found"; 510k "iVAPS" --jurisdiction US → unconfirmed: no record; 510k "VPAP ST-A" --applicant "ResMed" --jurisdiction US → verified, openFDA device/510k k_number=K161492; clearance-summary K161492 --expect-indication "iVAPS" --jurisdiction US → unconfirmed on the phrase, but only because that summary PDF uses a shifted subset-font encoding pypdf cannot map (every character offset by +29); decoded from the connector's own retrieved bytes, the IFU does contain "The iVAPS mode is indicated for patients weighing more than 66lbs (30 kg)". Flagged so a later reader does not read that phrase miss as a finding about the device.
claim 25unconfirmedUS
FTO/IP — no patent search was performed. The Generator ran no patent-database query for this candidate and identified no patent number, family or assignee patent list; the FTO field is unexamined, not clear. The two areas the Generator names as the specific risk surfaces, without having searched either, are (a) volume-assured / target-ventilation control algorithms of the kind marketed as iVAPS (ResMed) and AVAPS (Philips Respironics), and (b) transcutaneous CO2 sensor head construction, heating and calibration. A web search for a ResMed iVAPS patent number returned no number
jurisdiction: US — confidence: unconfirmed — note: still unexamined after this pass, and structurally so.patent takes a specific patent number and returns a record for it; there is no patent search connector in this repo, so an assignee-portfolio or subject-matter search — which is what both named risk…the full check surfaces require — cannot be run here at all, with or without an API key. No invocation was possible: a placeholder like patent <id> is refused by recheck_claims.py rather than guessed at, and inventing a plausible-looking patent number to have something to query would be fabrication. The claim's own statement — that the field is unexamined, not clear — is accurate and is now confirmed as still accurate. Two useful starting points did come out of this pass for whoever runs the search: the ResMed platform is cleared as K161492 "Juno VPAP ST-A" (iVAPS named in the IFU) and the Philips one as K102465, and the sensor surface sits under product code LKD with Sentec AG, Radiometer Medical and Perimed AB as the active assignee candidates (claim 19). Gate-relevant and unchanged: FTO/IP carries the rubric's only automatic kill and nothing has been searched — source: no search-capable patent connector exists in this repo; patent requires a specific patent_id and this file names none, so nothing was queried.
claim 26unconfirmedUS
FTO/IP, second claim — the foundational patents on bi-level positive airway pressure with a back-up rate, filed by the original commercial developers of that modality around 1990, are expected on their ordinary term to have expired, leaving the base modality free to practise
jurisdiction: US — confidence: unconfirmed — note: same structural block as claim 25 and for the same reason: no patent number is named, and patent cannot be run without one. Recording what would and would not follow even if it could: the connector returns filing and grant dates with an explicit naive-expiration…the full check caveat, so a verified result there would be a database fact about dates, never a legal FTO conclusion — term extensions, continuations, and later improvement patents on the same modality are all outside what it sees. So even the most favourable possible outcome on this claim would not clear the base modality; it would only date one document. The inference from the modality's age remains an inference — source: patent requires a specific patent_id; none is named in this file and none was invented, so nothing was queried.
claim 27unconfirmedUS
Assumption, not a fact: the idea depends on pulmonologists and sleep physicians choosing to prescribe a new entrant's respiratory assist device over the incumbent ResMed devices they already use, on the strength of the home tcCO2 channel. There is no connector for prescriber preference and no primary research behind this belief; it is written as an assumption so it stays visible
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research (interviews, a survey, a published preference study), and deliberately not answered from the Verifier's own judgement — a fluent model answer about what prescribers would do is a fabricated stakeholder opinion, not…the full check evidence. The checkable proxy hiding inside it is incumbent entrenchment, and part of that is now on the record: ResMed and Philips both hold current clearances on the bi-level-with-volume-assurance platforms (K161492, K102465) — source: adoption "pulmonologists and sleep physicians will prescribe a new entrant respiratory assist device over incumbent ResMed devices on the strength of a home tcCO2 channel" → unverifiable: asserts what clinicians, payers or patients would do; needs primary research.
claim 28unconfirmedUS
Assumption, not a fact: the idea depends on the DME supplier channel — Medicare RADs are dispensed and billed by DME suppliers, not sold directly to patients or practices — being willing to stock, set up and service a device carrying an extra consumable sensor, and on that extra service burden fitting inside the E0471 rental allowable. No supplier economics were researched
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed on the preference half; and the one quantitative half that is checkable in principle is blocked on a missing file, which is worth separating. "Does the extra service burden fit inside the E0471 rental allowable" needs the allowable, and the…the full check DMEPOS payment cache is absent here (claim 10) — so this assumption cannot even be framed numerically from this repo yet. That makes it a two-step item for whoever picks it up: retrieve the allowable first, then take supplier margin to primary research — source: adoption "DME suppliers will stock, set up and service a respiratory assist device carrying an extra consumable tcCO2 sensor inside the E0471 rental allowable" → unverifiable; payment E0471 --jurisdiction US → unconfirmed: no local cache at data/hcpcs_payment_rates.csv.
claim 29unconfirmedUS
Assumption, not a fact: the idea depends on patients with COPD tolerating and adhering to nightly high-intensity noninvasive ventilation at inspiratory pressures above 20 cm H2O, and on patients or caregivers applying a transcutaneous CO2 sensor correctly at home on the nights it is prescribed. HOT-HMV reports outcomes for a trial population under trial supervision; nothing here establishes adherence in ordinary practice
jurisdiction: US — confidence: unconfirmed — note: permanently unconfirmed absent primary research; not answered from Verifier judgement. Three facts from this pass sharpen it rather than settle it. (i) The pressure premise is loosely anchored at best: NCD 240.9 requires IPAP ≥ 15 cm H2O, not > 20 (claim 5), while…the full check HOT-HMV's median setting was 24 cm H2O (IQR 22-26) (claim 15) — so "above 20" is trial practice, not a coverage requirement, and the tolerability question could be reframed at the lower threshold. (ii) NCD 240.9 does impose a hard, auditable adherence bar for continued payment — use "at least 4 hours per 24-hour period, on at least 70% of days in a 30-day period", re-established at 6 months and again at 7-12 months — so adherence here is not only a clinical question but a revenue one. (iii) Nothing anywhere establishes at-home sensor application by patients or caregivers — source: adoption "patients with COPD will tolerate and adhere to nightly high-intensity NIV above 20 cm H2O and apply a transcutaneous CO2 sensor correctly at home" → unverifiable; adherence thresholds quoted from ncd 240.9 --jurisdiction US → verified, CMS Pub. 100-3, chapter 1 part 4, section=240.9.
claim 30unconfirmedUS
Assumption, not a fact: the idea depends on treating practitioners accepting a home overnight tcCO2 recording as an adequate basis for setting and documenting NIV settings in place of an attended in-laboratory titration, and on that substitution being acceptable for the documentation NCD 240.9 and LCD L33800 require. Whether the coverage documents permit or contemplate home-recorded CO2 at all was not checked
jurisdiction: US — confidence: unconfirmed — note: the practitioner-acceptance half is permanently unconfirmed absent primary research. The coverage-document half was checked this pass, and the answer is not comfortable. NCD 240.9 contains the word "transcutaneous" nowhere. Every CO2 measurement it specifies is…the full check arterial: entry requires "persistent hypercapnia as demonstrated by PaCO2 ≥ 52 mmHg by arterial blood gas during awake hours while breathing his/her prescribed FiO2", and the 6-month continuing criteria are framed on PaCO2 — "Normalization (< 46 mmHg) of PaCO2, or Stabilization of a rising PaCO2, or 20% reduction in PaCO2 from baseline value", or symptom improvement. The NCD also does not require an attended in-laboratory titration, and explicitly waives formal sleep testing where the clinician judges sleep apnea is not the predominant cause — so what the device would be displacing may not be a covered facility study in the first place, which cuts at the economic argument from the other side. Note carefully what this does and does not show: the NCD is silent on transcutaneous recording, which is not the same as prohibiting it, and the NCD's PaCO2 criteria are eligibility and outcome measures rather than titration documentation. LCD L33800, which is where documentation requirements would actually live, was not read — no connector reaches LCD text (claim 6). The Generator's instinct that this is the assumption most worth converting first is correct and this pass reinforces it — source: ncd 240.9 --expect "transcutaneous" --jurisdiction US → unconfirmed: "exists and was read, but its text does NOT contain the phrase 'transcutaneous'", CMS Pub. 100-3, chapter 1 part 4, section=240.9; adoption "treating practitioners will accept a home overnight tcCO2 recording in place of an attended in-laboratory titration for setting and documenting NIV settings" → unverifiable; coverage E0471 --jurisdiction US → unconfirmed: no local cache, LCD not reachable.
claim 31unverifiedUS
Medicare beneficiaries prescribed an E0471 respiratory assist device for CRF consequent to COPD will accept the beneficiary cost share on the capped-rental allowable, plus any non-covered charge for the reusable transcutaneous CO2 sensor and its consumables, without abandoning therapy.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 32unverifiedUS
A US clinical practice guideline or specialty-society recommendation endorses long-term home noninvasive ventilation for chronic hypercapnic COPD, and prescribing pulmonologists and sleep physicians cite it when deciding whether to initiate home NIV.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 33unverifiedUS
Adults with COPD, or their caregivers, can apply a reusable transcutaneous CO2 sensor at the ear or chest at home unaided and produce an overnight recording the treating practitioner judges interpretable.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (desirability deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 34unverifiedUS
A Medicare-payable HCPCS code, or an established payment mechanism inside the E0471 capped-rental allowable, covers the reusable transcutaneous CO2 sensor and its consumables so that the recording channel is not delivered unpaid.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 35unverifiedUS
A patentable claim is available over the integration of overnight transcutaneous CO2 recording with practitioner-approved bi-level titration recommendations that is not anticipated by ResMed's, Philips Respironics' or SenTec's existing filings.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 36unverifiedUS
Patients enrolled on an E0471 rental under NCD 240.9 sustain the NCD's continued-coverage adherence bar at re-establishment at 6 months and again at 7-12 months, at a rate high enough that monthly rental revenue continues through the capped-rental period.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (viability deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 37unverifiedUS
Overnight transcutaneous CO2 recorded at home with a reusable ear or chest sensor agrees with arterial PaCO2 closely enough, and drifts little enough across the night, to serve as the titration target for high-intensity noninvasive ventilation rather than only as an adjunct indicator of relative change.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 38unverifiedUS
FDA accepts a 510(k) for a combined home bi-level ventilator with an integrated overnight transcutaneous CO2 recording channel and practitioner-approved titration recommendations, without requiring a De Novo request or a clinical study.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 39unverifiedUS
A reusable transcutaneous CO2 sensor holds calibration across an unattended overnight home recording without mid-session recalibration or membrane change, at a skin-heating temperature that causes no thermal injury to elderly COPD patients.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it
claim 40unverifiedUS
The titration-recommendation software rejects overnight traces corrupted by sensor detachment, poor skin contact or artefact rather than computing a settings proposal from them, and presents the rejection to the treating practitioner.
jurisdiction: US — confidence: unverified — source: deck-surfaced assumption (feasibility deck, 2026-09-20) — never checked; recorded so the Verifier can see it